NeoGenomics (NEO) Fundamentals 2026 — Revenue Analysis | SniperIQ
NeoGenomics (NEO) is a US-listed Healthcare company in Medical - Diagnostics & Research with a market capitalization of
NeoGenomics (NEO) is a US-listed Healthcare company in Medical - Diagnostics & Research with a market capitalization of
NeoGenomics (NEO) has a market capitalization of approximately
NeoGenomics's trailing twelve-month P/E ratio is not meaningful (negative or nil earnings), with a price-to-book (P/B) of 0.4x. Valuation multiples are best compared with Healthcare sector peers rather than read in isolation.
NeoGenomics runs a net profit margin of -13.3%, a gross margin of 42.1%, and an operating margin of -13.9%. Margins and ROE indicate how efficiently the business converts sales into profit and shareholder returns.
NeoGenomics reported revenue of $727M for fiscal year 2025, with net income of -
NeoGenomics does not currently show a material trailing dividend yield; it is positioned more as a total-return name. Always confirm the latest dividend policy in the company's filings.
NeoGenomics carries a debt-to-equity ratio of 0.49x and a current ratio of 4.42x, with a market beta of 1.74. Lower leverage and a current ratio above 1.0 generally signal a stronger balance sheet.
SniperIQ provides research-only market intelligence, not personalised financial advice or a buy/sell call. For NeoGenomics (NEO) the key facts are: market cap
Get NeoGenomics's 8-quarter revenue and margin trend, peer comparison, DCF model, and AI signal on the SniperIQ research dashboard.